Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

MYSTERIOUS: Biogen s immunology pipeline has long term potential analyst - What They Never Told You

Biogen,World,Headquarters,At,225,Binney,St.,In,Cambridge,,Ma,

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.